Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Acorda Therapeutics Inc    ACOR

Delayed Quote. Delayed  - 08/29 10:00:00 pm
24.53 USD   +0.95%
07/28 ACORDA THERAPEU : reports 2Q loss
07/28 ACORDA THERAPEU : Provides Financial and Pipeline Update for Second ..
07/07 ACORDA THERAPEU : to Host Conference Call to Discuss Second Quarter ..
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/23/2016 08/24/2016 08/25/2016 08/26/2016 08/29/2016 Date
25.62(c) 24.29(c) 24.48(c) 24.3(c) 24.53(c) Last
424 760 436 908 433 592 414 174 312 086 Volume
-1.23% -5.19% +0.78% -0.74% +0.95% Change
More quotes
Financials ($)
Sales 2016 512 M
EBIT 2016 -11,7 M
Net income 2016 -34,1 M
Finance 2016 93,5 M
Yield 2016 -
Sales 2017 568 M
EBIT 2017 10,5 M
Net income 2017 -18,7 M
Finance 2017 77,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 2,03x
EV / Sales2017 1,86x
Capitalization 1 132 M
More Financials
Company
Acorda Therapeutics, Inc. develops and markets therapeutic products for nervous system disorders.The company's two main products are Ampyra and Zanaflex Capsules.The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short... 
More about the company
Surperformance© ratings of Acorda Therapeutics Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on ACORDA THERAPEUTICS INC
08/18 ACORDA THERAPEUTICS : Patent Issued for Compositions and Methods of Using Chondr..
08/15 ACORDA THERAPEUTICS INC : Other Events (form 8-K)
08/11 ACORDA THERAPEUTICS : Patent Issued for Compositions and Methods of Using Chondr..
08/04 ACORDA THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
08/04 ACORDA THERAPEUTICS : Assigned Patent
08/03 ACORDA THERAPEUTICS INC : Other Events (form 8-K)
07/28 ACORDA THERAPEUTICS INC : Results of Operations and Financial Condition, Financi..
07/28 ACORDA THERAPEUTICS : reports 2Q loss
07/28 ACORDA THERAPEUTICS : Provides Financial and Pipeline Update for Second Quarter ..
07/14 ACORDA THERAPEUTICS : Appoints Burkhard Blank, M.D., as Chief Medical Officer CM..
More news
Sector news : Bio Therapeutic Drugs
08/29DJSANOFI : Regeneron Announce Positive Trials for Cholesterol Drug
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/24DJAMGEN : FDA Rejects Amgen Hormonal-Imbalance Treatment
08/23DJPFIZER : to Acquire Key Drug -- WSJ
08/23DJDeal for Medivation Is the Latest In a Line of Similar Acquisitions -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
08/24 Acorda Therapeutics Can Deliver Sustained Growth
08/13 Tracking Seth Klarman's Baupost Group Holdings - Q2 2016 Update
08/05 Best And Worst Performing S&P 1500 Stocks YTD
08/01 Acorda Therapeutics (ACOR) CEO Ron Cohen on Q2 2016 Results - Earnings Call T..
07/28 Acorda Therapeutics misses by $0.13, misses on revenue
Advertisement
Chart ACORDA THERAPEUTICS INC
Duration : Period :
Acorda Therapeutics Inc Technical Analysis Chart | ACOR | US00484M1062 | 4-Traders
Full-screen chart
Technical analysis trends ACORDA THERAPEUTI...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 9
Average target price 39,7 $
Spread / Average Target 62%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ronald Cohen President, Chief Executive Officer & Director
David Lawrence Head-Business Operations
Michael W. Rogers Chief Financial Officer
Andrew R. Blight Chief Scientific Officer
Anthony O. Caggiano Vice President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ACORDA THERAPEUTICS IN..-42.66%1 132
AMGEN, INC.5.66%128 351
GILEAD SCIENCES, INC.-22.75%103 158
CELGENE CORPORATION-9.86%83 674
REGENERON PHARMACEUTIC..-26.43%42 053
VERTEX PHARMACEUTICALS..-22.96%24 020
More Results